FLUOGUIDE A/S DK -1 (96X) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) has a cash flow conversion efficiency ratio of -0.092x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.03 Million ≈ $-5.88 Million USD) by net assets (€54.53 Million ≈ $63.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 96X net asset quality score to measure how much of total assets are equity-financed.
FLUOGUIDE A/S DK -1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore FLUOGUIDE A/S DK -1 (96X) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
FLUOGUIDE A/S DK -1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FLUOGUIDE A/S DK -1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Selangor Dredging Bhd
KLSE:2224
|
0.216x |
|
Adolfo Dominguez SA
MC:ADZ
|
0.253x |
|
Do Day Dream Public Company Limited
BK:DDD
|
-0.001x |
|
TronicS Microsystems SA
PA:ALTRO
|
-0.435x |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
-0.008x |
|
Sherritt International Corporation
TO:S
|
0.024x |
|
Raphas Co. Ltd
KQ:214260
|
-0.045x |
|
Ionic Rare EARTHS Ltd
AU:IXR
|
-0.086x |
Annual Cash Flow Conversion Efficiency for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of FLUOGUIDE A/S DK -1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of FLUOGUIDE A/S DK -1.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €54.53 Million ≈ $63.75 Million |
€-36.96 Million ≈ $-43.21 Million |
-0.678x | +46.37% |
| 2024-12-31 | €23.07 Million ≈ $26.97 Million |
€-29.15 Million ≈ $-34.08 Million |
-1.264x | +49.46% |
| 2023-12-31 | €12.72 Million ≈ $14.87 Million |
€-31.81 Million ≈ $-37.19 Million |
-2.501x | -112.36% |
| 2022-12-31 | €31.97 Million ≈ $37.37 Million |
€-37.65 Million ≈ $-44.01 Million |
-1.178x | -202.57% |
| 2021-12-31 | €38.70 Million ≈ $45.25 Million |
€-15.06 Million ≈ $-17.61 Million |
-0.389x | -- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more